ÖZET
Amaç:
Bu çalışmada; romatoid artrit (RA) ve osteoporoz (OP) hastalarında interlökin (IL)-17 düzeylerinin sağlıklı kontrollere göre karşılaştırılması ve RA da hastalık aktivitesi, fonksiyonel durum ve OP varlığının IL-17 ile arasındaki ilişkisinin belirlenmesi amaçlanmıştır.
Gereç ve Yöntem:
Seksen beş hasta 4 grupta sınıflandırıldı. Grup 1: RA + OP (n=21), grup 2: RA (n=22), grup 3: 20 sağlıklı gönüllü, grup 4: OP (n=22). Demografik veriler, kemik dansitometresi değerleri, serum 25-hidroksi vitamin D ve IL-17 düzeyleri kaydedildi. Hastaların hastalık süreleri, ilaçları, ağrı düzeyleri ve hastalık aktiviteleri de kaydedildi ve hastalık aktiviteleri sağlık değerlendirme anketi ile değerlendirildi.
Bulgular:
RA olan ve olmayan hastaların IL-17 düzeyleri arasında fark saptanmadı (p>0,05). Benzer şekilde, hastalık aktivitesi ile IL-17 düzeyleri arasında bir ilişki saptamadık. Bununla birlikte, OP’si olmayan hastalarla karşılaştırıldığında, OP’li RA hastalarının IL-17 düzeyleri anlamlı olarak yüksek bulundu. OP’li RA hastalarında romatoid faktör ve IL-17 düzeyleri daha yüksekti. IL-17 ve lumbar T skoru ile femoral kemik mineral yoğunluğu arasında anlamlı, negatif korelasyon saptanırken, RA hastalarında diğer değişkenler arasında korelasyon saptanmadı.
Sonuç:
RA ve OP’de IL-17 seviyeleri yüksektir. RA’da IL-17 ile hastalık aktivitesi ve fonksiyonel durum arasında ilişki saptanmaz iken, OP’si olan RA’lı hastalarda IL-17 düzeyleri yüksektir.
References
1
Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6.
2
Orstavik RE, Haugeberg G, Mowinckel P, Høiseth A, Uhlig T, Falch JA, et al. Vertebral deformities in rheumatoid arthritis:a comparison with population-based controls. Arch Intern Med 2004;164:420-5.
3
Forsblad D’Elia H, Larsen A, Waltbrand E, Kvist G, Mellström D, Saxne T, et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003;62:617-23.
4
Sinigaglia L, Varenna M, Girasole G, Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin N Am 2006;32:631-58.
5
Abdel Meguid MH, Hamad YH, Swilam RS, Barakat MS. Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int 2013;33:697-703.
6
Caetano-Lopes J, Rodrigues A, Lopes A, Vale AC, Pitts-Kiefer MA, Vidal B, et al. Rheumatoid Arthritis Bone Fragility Is Associated With Upregulation of IL17 and DKK1 Gene Expression. Clin Rev Allergy Immunol 2014;47:38-45.
7
Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T,et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007;204:41-7.
8
Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-74.
9
Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004;61:567-79.
10
Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
11
Lee Y. The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases. BMB Rep 2013;46:479-83.
12
Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 2007;79:5462-73.
13
Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006;177:36-9.
14
Li X, Yuan FL, Lu WG, Zhao YQ, Li CW, Li JP, et al. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 2010;397:131-5.
15
Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cells 2005;19:180-4.
16
Metawi SA, Abbas D, Kamal MM, Ibrahim MK. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011;30:1201-7.
17
Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Diseases activity score-28 values differ considerably depending on patient’s pain perception and sex. J Rheumatol 2007;34:2382-7.
18
Krishman E, Tugwell F, Fries JF. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as quality indicator (QI). Arthritis Res Ther 2004;6:505-13.
19
Melis L, Vandooren B, Kruithof E, Jacques P, De Vos M, Mielants H, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010;69:618-23.
20
Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol 2004;31:2336-46.
21
Kohno M, Tsutsumi A, Matsui H, Sugihara M, Suzuki T, Mamura M, et al. Interleukin-17 gene expression in patients with rheumatoid arthritis. Mod Rheumatol 2008;18:15-22.
22
Tofiq DM, Merza RR. Assessment of the role of IL-17A in rheumatoid arthritis patients; in sulaymaniyah governorate. Eur Sci J 2015;11:358-72.
23
Ziolkowska M, Koc A, Luszczkiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000;164:2832-8.
24
Shahrara S, Huang Q, Mandelin AM, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008;10:93.
25
Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi JI, Kaibara N, et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:1299-304.
26
Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, et al. Combined inhibition of tumor necrosis factor a and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015;67:51-62.
27
Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170:2655-62.
28
Kramer JM, Gaffen SL. Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy. J Periodontol 2007;78:1083-93.
29
Zhang J, Fu Q, Ren Z, Wang Y, Wang C, Shen T, et al. Changes of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosis. Gynecol Endocrinol 2015;31:183-90.
30
Tyagi AM, Srivastava K, Mansoori MN, Trivedi R, Chattopadhyay N, Singh D. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One 2012;7:e44552.
31
DeSelm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, et al. IL-17 mediates estrogendeficient osteoporosis in an Act1-dependent manner. J Cell Biochem 2012;113:2895-902.
32
Molnar I, Bohaty I, Somogyine-Vari E. High prevalence of increased interleukin-17A serum levels in postmenopausal estrogen deficiency. Menopause 2014;21:749-52.
33
Al-Saadany HM, Hussein MS, Gaber RA, Zaytoun HA. Th-17 cells and serum IL-17 in rheumatoid arthritis patients: Correlation with disease activity and severity. The Egyptian Rheumatologist 2016;38:1-7.
